Results 51 to 60 of about 15,755 (201)

Bioinorganic Site‐Specific Conjugation of Multi‐Arm Linkers to Create Pharmaceuticals With Targeting and Effector Functions

Journal of the Chinese Chemical Society, EarlyView.
This Account showcases a modular, multi‐arm linker platform that decouples payload loading from antibody conjugation. By leveraging a computationally designed ACPGHA zinc‐binding motif, we demonstrate the construction of homogeneous antibody‐drug conjugates and theranostic antibody‐radionuclide conjugates with high payload loading. The multi‐arm linker
Cédric Grauffel, Tse Wen Chang, Carmay Lim   +2 more
wiley   +1 more source

Daratumumab-induced transient myopic shift

American Journal of Ophthalmology Case Reports, 2019
Purpose: To describe an unprecedented case of transient myopic shift induced by a chemotherapeutic agent, daratumumab. Observations: A 43-year-old emmetropic female with multiple myeloma experienced sudden onset of myopic shift during her first ...
Maria A. Mavrommatis, Hoon Jung, Ajai Chari, Bart Barlogie, James G. Chelnis   +4 more
doaj   +1 more source

Case report: Daratumumab for treatment of refractory late or chronic active antibody-mediated rejection in renal allograft recipients with high levels of de novo donor-specific antibodies

Frontiers in Immunology, 2023
BackgroundLate or chronic active antibody-mediated rejection (AMR) associated with de novo donor-specific antibodies (dnDSA) after renal transplantation is a great clinical challenge because it is often resistant to conventional therapies.
Lan Zhu, Lan Zhu, Lan Zhu, Lan Zhu, Zhiliang Guo, Daqiang Zhao, Daqiang Zhao, Daqiang Zhao, Daqiang Zhao, Rula Sa, Guangyuan Zhao, Guangyuan Zhao, Guangyuan Zhao, Guangyuan Zhao, Hui Guo, Hui Guo, Hui Guo, Hui Guo, Gang Chen, Gang Chen, Gang Chen, Gang Chen   +21 more
doaj   +1 more source

Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma [PDF]

, 2023
Although treatment of multiple myeloma (MM) with daratumumab significantly extends the patient's lifespan, resistance to therapy is inevitable. ISB 1342 was designed to target MM cells from patients with relapsed/refractory MM (r/r MM) displaying lower ...
Berret, Jérémy, Blein, Stanislas, Borthakur, Gautam, Carretero-Iglesia, Laura, Chimen, Myriam, Doucey, Marie-Agnès, Drake, Adam, Edwards, Claire, Edwards, James, Estoppey, Carole, Gudi, Girish S, Kaya, Zeynep, Kervoëlen, Charlotte, Laurendon, Amélie, Macoin, Julie, Maiti, Abhishek, Matthes, Thomas, Mbow, M Lamine, Menon, Vinu, Menoret, Emmanuelle, Monney, Thierry, Moreau, Philippe, Nallet, Emilie, Pais Ferreira, Daniela, Pellat-Deceunynck, Catherine, Perro, Mario, Pihlgren, Maria, Pouleau, Blandine, Srivastava, Ankita, Suere, Perrine, Udupa, Venkatesha, Zhukovsky, Eugene   +31 more
core   +2 more sources

A Refractory Leg Skin Ulcer Associated With Multiple Myeloma Successfully Treated With Plasma Exchange, Lenalidomide, and Dexamethasone

JEADV Clinical Practice, EarlyView.
ABSTRACT Multiple myeloma (MM) is a malignant plasma cell disorder that primarily presents with CRAB symptoms (calcium elevation, renal failure, anemia, and bone abnormalities). In rare cases, MM manifests with systemic complications like skin ulcers, which present management challenges. Here, we report a 78‐year‐old Japanese man with MM and refractory
Naoko Hattori, Yutaka Kuwatsuka, Tomoka Waseda, Daisuke Ehara, Koji Ando, Hiroyuki Murota   +5 more
wiley   +1 more source

Serological responses against seasonal influenza viruses in patients with multiple myeloma treated or untreated with daratumumab after two doses of tetravalent vaccine

International Journal of Infectious Diseases
Objectives: Daratumumab-treated myeloma patients may face increased seasonal influenza risk due to weakened postvaccination immune responses, especially with daratumumab treatment.
Simon B. Gressens, Vincent Enouf, Antoine Créon, Giovanna Melica, Francois Lemonnier, Jehan Dupuis, Taoufik El Gnaoui, Mohammad Hammoud, Karim Belhadj, Corinne Haioun, Anne Le Bouter, Sebastien Gallien, Fabien Le Bras, Slim Fourati   +13 more
doaj   +1 more source

Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion

Asia-Pacific Journal of Oncology Nursing, 2018
Patients with multiple myeloma (MM) are typically of an advanced age and may have significant co-existing medical conditions. They have often had multiple lines of therapy and as such experience disease-related effects alongside associated treatment ...
Tracy King, Jacqueline Jagger, Jodie Wood, Carmel Woodrow, Alicia Snowden, Sally Haines, Christina Crosbie, Kristen Houdyk   +7 more
doaj   +1 more source

Therapeutic Options for IgA Pemphigus in Patients Refractory to Dapsone

JEADV Clinical Practice, EarlyView.
ABSTRACT IgA pemphigus is a rare autoimmune blistering disorder with limited therapeutic guidance available due to its rarity and complex presentation. This comprehensive analysis evaluates the therapeutic outcomes of 67 published patients, emphasising the significant role of dapsone as the first‐line treatment.
Lorenz Frasheri, Marta Dechant, Tilo Biedermann   +2 more
wiley   +1 more source

Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?

Cells, 2020
During a time span of just a few years, the CD38 antibody, daratumumab, has been established as one of the most important new drugs for the treatment of multiple myeloma, both in the relapsed/refractory setting and, more recently, as a first-line ...
Torben Plesner, Niels W. C. J. van de Donk, Paul G. Richardson   +2 more
doaj   +1 more source

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

Haematologica, 2011
Background In our efforts to develop novel effective treatment regimens for multiple myeloma we evaluated the potential benefits of combining the immunomodulatory drug lenalidomide with daratumumab.
Michael. S. van der Veer, Michel de Weers, Berris van Kessel, Joost M. Bakker, Shulamiet Wittebol, Paul W.H.I. Parren, Henk M. Lokhorst, Tuna Mutis   +7 more
doaj   +1 more source